176 related articles for article (PubMed ID: 35413808)
1. The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: an ambispective cohort study.
Rachman A; Wafa S; Nugroho P; Koesnoe S
BMC Cancer; 2022 Apr; 22(1):395. PubMed ID: 35413808
[TBL] [Abstract][Full Text] [Related]
2. Effect of mannitol on acute kidney injury induced by cisplatin.
Bégin AM; Monfette ML; Boudrias-Dalle É; Lavallée E; Samouelian V; Soulières D; Chagnon M; Fournier MA; Letarte N; Adam JP
Support Care Cancer; 2021 Apr; 29(4):2083-2091. PubMed ID: 32862356
[TBL] [Abstract][Full Text] [Related]
3. Effect of mannitol-based reduced-volume hydration on kidney function in concomitant cisplatin-based chemoradiation for head-and-neck squamous cell carcinoma.
Paschen C; Moll M; Altorjai G; Hecking M; Fuereder T; Widder J; Herrmann H
Head Neck; 2023 Aug; 45(8):2087-2097. PubMed ID: 37345576
[TBL] [Abstract][Full Text] [Related]
4. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
El Hamamsy M; Kamal N; Bazan NS; El Haddad M
Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
8. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
[TBL] [Abstract][Full Text] [Related]
11. Mannitol is an independent risk factor of acute kidney injury after cerebral trauma: a case-control study.
Fang L; You H; Chen B; Xu Z; Gao L; Liu J; Xie Q; Zhou Y; Gu Y; Lin S; Ding F
Ren Fail; 2010 Jul; 32(6):673-9. PubMed ID: 20540634
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage.
Kim MY; Park JH; Kang NR; Jang HR; Lee JE; Huh W; Kim YG; Kim DJ; Hong SC; Kim JS; Oh HY
J Neurosurg; 2014 Jun; 120(6):1340-8. PubMed ID: 24484224
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.
Motwani SS; McMahon GM; Humphreys BD; Partridge AH; Waikar SS; Curhan GC
J Clin Oncol; 2018 Mar; 36(7):682-688. PubMed ID: 29320311
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin.
Ghadrdan E; Ebrahimpour S; Sadighi S; Chaibakhsh S; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Oct; 26(7):1643-1649. PubMed ID: 32046578
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Risk Factors for Acute Kidney Injury Following Mannitol Infusion in Patients With Acute Stroke: A Retrospective Cohort Study.
Lin SY; Tang SC; Tsai LK; Yeh SJ; Shen LJ; Wu FL; Jeng JS
Medicine (Baltimore); 2015 Nov; 94(47):e2032. PubMed ID: 26632702
[TBL] [Abstract][Full Text] [Related]
16. Intravascular administration of mannitol for acute kidney injury prevention: a systematic review and meta-analysis.
Yang B; Xu J; Xu F; Zou Z; Ye C; Mei C; Mao Z
PLoS One; 2014; 9(1):e85029. PubMed ID: 24454783
[TBL] [Abstract][Full Text] [Related]
17. Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic stem cell transplantation: effect of aminoglycoside therapy.
Cooper BW; Creger RJ; Soegiarso W; Mackay WL; Lazarus HM
Am J Med; 1993 May; 94(5):497-504. PubMed ID: 8098904
[TBL] [Abstract][Full Text] [Related]
18. Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
Morgan KP; Snavely AC; Wind LS; Buie LW; Grilley-Olson J; Walko CM; Weiss J
Ann Pharmacother; 2014 Jul; 48(7):863-869. PubMed ID: 24778426
[TBL] [Abstract][Full Text] [Related]
19. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
Morgan KP; Buie LW; Savage SW
Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
[TBL] [Abstract][Full Text] [Related]
20. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
